Patents by Inventor Christopher Chien

Christopher Chien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF
    Publication number: 20220127367
    Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien
  • Human monoclonal antibodies specific for FLT3 and uses thereof
    Patent number: 11236171
    Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 1, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien, Haiying Qin
  • HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF
    Publication number: 20190352408
    Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.
    Type: Application
    Filed: December 21, 2017
    Publication date: November 21, 2019
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien